Skip to content

Study · Randomized controlled trial · n = 1,202 · 2022

6 results

Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, Krop J, Clayton AH

Journal of women's health (2002)25 Feb 2022Cited by 6 (Europe PMC)

PMID35230162 (opens in a new tab)DOI10.1089/jwh.2021.0225 (opens in a new tab)PepBankPUB-35230162
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with HSDD, bremelanotide improved sexual desire versus placebo across age, weight, BMI and bioavailable testosterone subgroups, with few exceptions.

    In plain wordsIn women with low sexual desire, bremelanotide raised desire more than placebo across age, weight, BMI and testosterone groups, with few exceptions.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseSexual desire across age, weight, BMI and testosterone subgroups
    Study

    n = 1,202

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.75 mg · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Among 1202 patients included in the integrated and subgroup analyses, bremelanotide achieved statistically significant improvements in measures of increased desire and decreased distress associated with low desire across all age, weight, and BMI subgroups, and all baseline bioavailable testosterone…
    1 context sentence
    Summary · context
    Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desi…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with HSDD, bremelanotide reduced distress associated with low desire versus placebo across age, weight, BMI and bioavailable testosterone subgroups, with few exceptions.

    In plain wordsIn women with low sexual desire, bremelanotide reduced distress more than placebo across age, weight, BMI and testosterone groups, with few exceptions.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseDesire-related distress across age, weight, BMI and testosterone subgroups
    Study

    n = 1,202

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.75 mg · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Among 1202 patients included in the integrated and subgroup analyses, bremelanotide achieved statistically significant improvements in measures of increased desire and decreased distress associated with low desire across all age, weight, and BMI subgroups, and all baseline bioavailable testosterone…
    1 context sentence
    Summary · context
    Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desi…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with HSDD not taking hormonal contraceptives, bremelanotide significantly increased reported sexual desire versus placebo.

    In plain wordsIn women not taking hormonal contraceptives, bremelanotide raised sexual desire more than placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseSexual desire in women not taking hormonal contraceptives
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.75 mg · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Bremelanotide was further associated with statistically significant increases in reported sexual desire (p < 0.05) in patients not taking hormonal contraceptives, and with a numerical advantage in those taking hormonal contraceptives.
    1 context sentence
    Summary · context
    Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desi…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with HSDD taking hormonal contraceptives, bremelanotide showed a numerical advantage in sexual desire versus placebo; the abstract does not report statistical significance for this subgroup.

    In plain wordsIn women taking hormonal contraceptives, bremelanotide showed a numerical advantage in desire over placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeSexual desire in women taking hormonal contraceptives
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.75 mg · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    with a numerical advantage in those taking hormonal contraceptives.
    1 context sentence
    Summary · context
    Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desi…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with HSDD, bremelanotide significantly reduced distress versus placebo regardless of hormonal contraceptive use.

    In plain wordsIn women with low sexual desire, bremelanotide reduced distress more than placebo, whether or not they used hormonal contraceptives.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseDesire-related distress regardless of hormonal contraceptive use
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.75 mg · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients treated with bremelanotide experienced decreased distress compared with those in the placebo group at levels of statistical significance (p < 0.05) regardless of hormonal contraceptive use.
    1 context sentence
    Summary · context
    Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desi…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with HSDD, bremelanotide produced statistically significant improvements versus placebo with or without decreased arousal and regardless of HSDD duration.

    In plain wordsIn women with low sexual desire, bremelanotide improved symptoms more than placebo with or without low arousal, however long the condition had lasted.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseImprovement by presence of decreased arousal and HSDD duration
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    1.75 mg · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Statistically significant improvements were observed in the presence or absence of decreased arousal, and regardless of HSDD duration.
    1 context sentence
    Summary · context
    Patients self-administered bremelanotide 1.75 mg or placebo subcutaneously using an autoinjector, as needed, before sexual activity for 24 weeks. Efficacy was assessed using change from baseline to end-of-study for Female Sexual Function Index desire domain and Female Sexual Distress Scale-Desi…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.